Drug Trial Radar · NCT06935175
A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
Last checked: Nov 19, 2026Latest source record: Apr 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
53
Planned (sponsor's estimate)
Start
May 1, 2025
Primary completion
May 31, 2027
Study completion May 31, 2028
Sponsor
- Lead sponsor
- Shanghai Zhongshan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study was designed to evaluate the efficacy and safety of SHR-1826 monotherapy or in combination with immunotherapy in the treatment of advanced hepatocellular cancer patients.
Conditions
- Hepatocellular Cancer
Interventions
SHR-1826Drug
SHR-1826 will be administrated per dose level in which the patients are assigned.
SHR-1826 and immunotherapy combination therapyDrug
SHR-1826 and immunotherapy will be administrated per dose level in which the patients are assigned.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) by RECIST V1.1Time frame: up 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Zhongshan Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.